Last reviewed · How we verify
Capecitabine, 5-fluorouracil
Capecitabine, 5-fluorouracil is a Small molecule drug developed by The Netherlands Cancer Institute. It is currently in Phase 1 development. Also known as: Xeloda, Capecitabine, Fluorouracil, 5-Fluorouracil.
At a glance
| Generic name | Capecitabine, 5-fluorouracil |
|---|---|
| Also known as | Xeloda, Capecitabine, Fluorouracil, 5-Fluorouracil, 5-FU |
| Sponsor | The Netherlands Cancer Institute |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nausea
- Anaemia
- Diarrhoea
- Neutropenia
- Decreased appetite
- Vomiting
- Fatigue
- Neutrophil count decreased
- Constipation
- Asthenia
- Weight decreased
- Palmar-plantar erythrodysaesthesia syndrome
Key clinical trials
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Pan Tumor Rollover Study (PHASE2)
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (PHASE3)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body (PHASE3)
- Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study (PHASE2)
- Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer (NA)
- A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Capecitabine, 5-fluorouracil CI brief — competitive landscape report
- Capecitabine, 5-fluorouracil updates RSS · CI watch RSS
- The Netherlands Cancer Institute portfolio CI
Frequently asked questions about Capecitabine, 5-fluorouracil
What is Capecitabine, 5-fluorouracil?
Capecitabine, 5-fluorouracil is a Small molecule drug developed by The Netherlands Cancer Institute.
Who makes Capecitabine, 5-fluorouracil?
Capecitabine, 5-fluorouracil is developed by The Netherlands Cancer Institute (see full The Netherlands Cancer Institute pipeline at /company/the-netherlands-cancer-institute).
Is Capecitabine, 5-fluorouracil also known as anything else?
Capecitabine, 5-fluorouracil is also known as Xeloda, Capecitabine, Fluorouracil, 5-Fluorouracil, 5-FU.
What development phase is Capecitabine, 5-fluorouracil in?
Capecitabine, 5-fluorouracil is in Phase 1.
What are the side effects of Capecitabine, 5-fluorouracil?
Common side effects of Capecitabine, 5-fluorouracil include Nausea, Anaemia, Diarrhoea, Neutropenia, Decreased appetite, Vomiting.
Related
- Manufacturer: The Netherlands Cancer Institute — full pipeline
- Also known as: Xeloda, Capecitabine, Fluorouracil, 5-Fluorouracil, 5-FU
- Compare: Capecitabine, 5-fluorouracil vs similar drugs
- Pricing: Capecitabine, 5-fluorouracil cost, discount & access